# Adenylyl cyclase 1 as a Therapy Target for Ethanol-Induced Neuroplastic Deficits

> **NIH VA IK2** · JOHN D DINGELL VA MEDICAL CENTER · 2020 · —

## Abstract

   
DESCRIPTION:          
The application is a third submission of a CDA-2 that has been reviewed by a VA review panel twice before.  The previous application was reviewed favorably with the majority of the negative comments being related to the mentoring program.  In addition, there were some small comments related to the specificity of the effect and the region of the brain to be studied and the
use of pharmacological inhibitors.  The author has responded very strongly scientifically by adding figures 8 and 14 to the revised proposal where she shows that ethanol intake is significantly decreased in the AC1 inhibitor group.  I think this is a thorough response to the scientific portion.  Regarding mentoring, the applicant has provided more information regarding the productivity, seniority and the training to be provided by Dr. Conti.  In my opinion, this response was less convincing.  My overall level of enthusiasm is only moderate.

## Key facts

- **NIH application ID:** 9795376
- **Project number:** 5IK2RX001623-05
- **Recipient organization:** JOHN D DINGELL VA MEDICAL CENTER
- **Principal Investigator:** Kelly Bosse
- **Activity code:** IK2 (R01, R21, SBIR, etc.)
- **Funding institute:** VA
- **Fiscal year:** 2020
- **Award amount:** —
- **Award type:** 5
- **Project period:** 2015-11-01 → 2021-10-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9795376

## Citation

> US National Institutes of Health, RePORTER application 9795376, Adenylyl cyclase 1 as a Therapy Target for Ethanol-Induced Neuroplastic Deficits (5IK2RX001623-05). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9795376. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*